シルデナフィルの中国市場

調査会社China Research and Intelligence社が発行したリサーチレポート(データ管理コード:DATA8102364)
◆英語タイトル:Investigation Report on China's Sildenafil Market, 2018-2022
◆発行会社/調査会社:China Research and Intelligence
◆商品コード:DATA8102364
◆発行日:2018年9月
◆調査対象地域:中国
◆産業分野:製薬
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,200 ⇒換算¥248,600見積依頼/購入/質問フォーム
EnterprisewideUSD3,300 ⇒換算¥372,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[シルデナフィルの中国市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DescriptionAccording to statistics, more than 60% of Chinese men aged 35 and above suffer from sexual dysfunction.
Sildenafil is developed by Pfizer to treat penile erectile dysfunction, pulmonary hypertension, mountain sickness, etc. Pfizer’s application for Viagra’s patent was approved by China’s State Intellectual Property Office in 1994. According to the patent law of China, the patent should be valid for 20 years till 2014. After the expiration of the patent, pharmaceutical companies can produce Sildenafil as long as they have obtained the approval. Therefore, Chinese manufacturers began to launch Sildenafil in 2014. CRI’s market investigation shows that China’s Sildenafil market is dominated by Pfizer’s Viagra, Baiyunshan’s Jinge and Yabang Aipusen’s Wanfeile. The market share of Pfizer’s Viagra, either by sales volume or by sales value, exceeded 90% in 2017. However, it will decrease as China-made counterparts are launched.
The number of erectile dysfunction patients will continue to rise in the next few years as the economy develops, the lifestyle changes, and psychological pressures increase in China. Furthermore, Sildenafil is becoming more affordable with the rise of income in China. The sales value of Sildenafil exceeded CNY 30 million in 2017, and the market will continue to grow in the next few years.

Topics Covered:
- Development environment of China’s Sildenafil market
- Sales of Sildenafil in China
- Competition pattern of China’s Sildenafil market
- Prices of Sildenafil in China’s Hospitals
- Driving forces and market opportunities for China’s Sildenafil market
- Prospect of China’s Sildenafil market

*** レポート目次(コンテンツ)***

Table of Contents
1 Relevant Concepts of Sildenafil
1.1 Indications for Sildenafil
1.2 Development History of Sildenafil in China
1.3 Patents and Government Approval on Sildenafil in China

2 Sales of Sildenafil in China, 2013-2017
2.1 Sales Value
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Sildenafil by Dosage Form in China, 2013-2017

3 Analysis on Major Sildenafil Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Sildenafil Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer’s Sildenafil in China
3.3 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (“Baiyunshan”)
3.4 Jiangsu Yabang Aipusen Pharmaceutical Co., Ltd. (“Yabang Aipusen”)

4 Prices of Sildenafil in China, 2017-2018
4.1 Pfizer (Viagra)
4.2 Baiyunshan (Jinge)
4.3 Yabang Aipusen (Wanfeile)

5 Prospect of China’s Sildenafil Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Sales of Sildenafil in China, 2013-2017
Chart Sales Value of Sildenafil in Parts of China, 2013-2017
Chart Sales Volume of Sildenafil in China, 2013-2017
Chart Sales Volume of Sildenafil in Parts of China, 2013-2017
Chart Sales Value of Pfizer’s Sildenafil, 2013-2017
Chart Sales Volume of Pfizer’s Sildenafil, 2013-2017
Chart Sales Value of Baiyunshan’s Sildenafil, 2013-2017
Chart Sales Value of Yabang Aipusen’s Sildenafil, 2013-2017
Chart Prices of Pfizer’s Sildenafil (Viagra) in Parts of China in 2017
Chart Prices of Baiyunshan’s Sildenafil (Jinge) in Parts of China in 2017
Chart Governmental Approval of Sildenafil in China
Chart Sales Value of Sildenafil in China, 2013-2017
Chart Forecast on Sales Value of Sildenafil in China, 2018-2022



*** レポートのキーワード ***

シルデナフィル

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA8102364 )"シルデナフィルの中国市場" (英文:Investigation Report on China's Sildenafil Market, 2018-2022)はChina Research and Intelligence社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。